Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA) : A randomized, controlled, open-label trial
Copyright: © 2023 Sundén-Cullberg et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited..
BACKGROUND: Anakinra and tocilizumab are used for severe Covid-19, but only one previous randomized controlled trial (RCT) has studied both. We performed a multi-center RCT comparing anakinra or tocilizumab versus usual care (UC) for adults at high risk of deterioration.
METHODS: The study was conducted June 2020 to March 2021. Eligibility required ≥ 5 liters/minute of Oxygen to maintain peripheral oxygen saturation at ≥ 93%, CRP > 70 mg/L, ferritin > 500 μg/L and at least two points where one point was awarded for lymphocytes < 1x 109/L; D-dimer ≥ 0.5 mg/L and; lactate dehydrogenase ≥ 8 microkatal/L. Patients were randomly assigned 1:1:1 to receive either a single dose of tocilizumab (8 mg/kg) or anakinra 100 mg IV QID for seven days or UC alone. The primary outcome was time to recovery.
RESULTS: Recruitment was ended prematurely when tocilizumab became part of usual care. Out of a planned 195 patients, 77 had been randomized, 27 to UC, 28 to anakinra and 22 to tocilizumab. Median time to recovery was 15, 15 and 11 days. Rate ratio for recovery for UC vs anakinra was 0.91, 0.47 to 1.78, 95% [CI], p = 0.8 and for UC vs tocilizumab 1.13, 0.55 to 2.30; p = 0.7. There were non-significant trends favoring tocilizumab (and to limited degree anakinra) vs UC for some secondary outcomes. Safety profiles did not differ significantly.
CONCLUSION: Premature closure of trial precludes firm conclusions. Anakinra or tocilizumab did not significantly shorten time to clinical recovery compared to usual care. (IMMCoVA, NCT04412291, EudraCT: 2020-00174824).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
PloS one - 18(2023), 12 vom: 29., Seite e0295838 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sundén-Cullberg, Jonas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
I031V2H011 |
|---|
| Anmerkungen: |
Date Completed 03.01.2024 Date Revised 04.01.2024 published: Electronic-eCollection ClinicalTrials.gov: NCT04412291 Citation Status MEDLINE |
|---|
| doi: |
10.1371/journal.pone.0295838 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366479970 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366479970 | ||
| 003 | DE-627 | ||
| 005 | 20240108141756.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.pone.0295838 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1248.xml |
| 035 | |a (DE-627)NLM366479970 | ||
| 035 | |a (NLM)38157348 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sundén-Cullberg, Jonas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA) |b A randomized, controlled, open-label trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2024 | ||
| 500 | |a Date Revised 04.01.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a ClinicalTrials.gov: NCT04412291 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright: © 2023 Sundén-Cullberg et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | ||
| 520 | |a BACKGROUND: Anakinra and tocilizumab are used for severe Covid-19, but only one previous randomized controlled trial (RCT) has studied both. We performed a multi-center RCT comparing anakinra or tocilizumab versus usual care (UC) for adults at high risk of deterioration | ||
| 520 | |a METHODS: The study was conducted June 2020 to March 2021. Eligibility required ≥ 5 liters/minute of Oxygen to maintain peripheral oxygen saturation at ≥ 93%, CRP > 70 mg/L, ferritin > 500 μg/L and at least two points where one point was awarded for lymphocytes < 1x 109/L; D-dimer ≥ 0.5 mg/L and; lactate dehydrogenase ≥ 8 microkatal/L. Patients were randomly assigned 1:1:1 to receive either a single dose of tocilizumab (8 mg/kg) or anakinra 100 mg IV QID for seven days or UC alone. The primary outcome was time to recovery | ||
| 520 | |a RESULTS: Recruitment was ended prematurely when tocilizumab became part of usual care. Out of a planned 195 patients, 77 had been randomized, 27 to UC, 28 to anakinra and 22 to tocilizumab. Median time to recovery was 15, 15 and 11 days. Rate ratio for recovery for UC vs anakinra was 0.91, 0.47 to 1.78, 95% [CI], p = 0.8 and for UC vs tocilizumab 1.13, 0.55 to 2.30; p = 0.7. There were non-significant trends favoring tocilizumab (and to limited degree anakinra) vs UC for some secondary outcomes. Safety profiles did not differ significantly | ||
| 520 | |a CONCLUSION: Premature closure of trial precludes firm conclusions. Anakinra or tocilizumab did not significantly shorten time to clinical recovery compared to usual care. (IMMCoVA, NCT04412291, EudraCT: 2020-00174824) | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 650 | 7 | |a Interleukin 1 Receptor Antagonist Protein |2 NLM | |
| 700 | 1 | |a Chen, Puran |e verfasserin |4 aut | |
| 700 | 1 | |a Häbel, Henrike |e verfasserin |4 aut | |
| 700 | 1 | |a Skorup, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Janols, Helena |e verfasserin |4 aut | |
| 700 | 1 | |a Rasmuson, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Niward, Katarina |e verfasserin |4 aut | |
| 700 | 1 | |a Östholm Balkhed, Åse |e verfasserin |4 aut | |
| 700 | 1 | |a Chatzidionysiou, Katerina |e verfasserin |4 aut | |
| 700 | 1 | |a Asgeirsson, Hilmir |e verfasserin |4 aut | |
| 700 | 1 | |a Blennow, Ola |e verfasserin |4 aut | |
| 700 | 1 | |a Parke, Åsa |e verfasserin |4 aut | |
| 700 | 1 | |a Svensson, Anna-Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Muvva, Jagadeeswara Rao |e verfasserin |4 aut | |
| 700 | 1 | |a Ljunggren, Hans-Gustav |e verfasserin |4 aut | |
| 700 | 0 | |a Karolinska KI/K COVID-19 Treatment Working Group |e verfasserin |4 aut | |
| 700 | 1 | |a Horne, Anna-Carin |e verfasserin |4 aut | |
| 700 | 1 | |a Ådén, Ulrika |e verfasserin |4 aut | |
| 700 | 1 | |a Henter, Jan-Inge |e verfasserin |4 aut | |
| 700 | 1 | |a Sönnerborg, Anders |e verfasserin |4 aut | |
| 700 | 1 | |a Vesterbacka, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Nowak, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Lampa, Jon |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PloS one |d 2006 |g 18(2023), 12 vom: 29., Seite e0295838 |w (DE-627)NLM167327399 |x 1932-6203 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:12 |g day:29 |g pages:e0295838 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pone.0295838 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 12 |b 29 |h e0295838 | ||